Who owns Alnylam Pharmaceuticals?

Key details on Alnylam Pharmaceuticals (Ticker: ALNY)

Who owns Alnylam Pharmaceuticals?

Is ALNY a good stock to own? Find out who bought Alnylam Pharmaceuticals, who sold Alnylam Pharmaceuticals (ALNY) stock, and who holds a large position in Alnylam Pharmaceuticals.

Fund Name Number of Shares Share Valuation As Of
Vanguard 16.25M $1.31B Sept. 30, 2015
FMR 12.69M $1.02B Sept. 30, 2015
Wellington Management Company 10.32M $829.65M Sept. 30, 2015
Franklin Resources 2.14M $207.43M Dec. 31, 2014
Capital World Investors^ 1.94M $156.19M Sept. 30, 2015
UBS GLOBAL ASSET MANAGEMENT AMERICAS 1.91M $153.61M Sept. 30, 2015
Columbia Wanger Asset Management 1.91M $122.87M Dec. 31, 2013
BlackRock Fund Advisors 1.90M $152.98M Sept. 30, 2015
HealthCor Management 1.80M $16.87M June 30, 2011
BlackRock Institutional Trust Company, N.A. 1.76M $141.56M Sept. 30, 2015
Schroder Investment Management 1.64M $105.18M Sept. 30, 2013
STATE STREET CORPORATION 1.55M $124.33M Sept. 30, 2015
Jennison Associates 1.48M $119.11M Sept. 30, 2015
Gilder, Gagnon, Howe & Co 1.48M $139.08M Dec. 31, 2015
HealthCor Management 1.45M $35.34M March 31, 2013
Falcon Edge Capital 1.37M $132.67M Dec. 31, 2014
Bridger Management 1.37M $33.31M March 31, 2013
T. Rowe Price Associates 1.32M $106.09M Sept. 30, 2015
Abingworth 1.31M $24.69M Sept. 30, 2012
Camber Capital Management 1.28M $14.17M March 31, 2012
First Trust Advisors 1.22M $115.18M Dec. 31, 2015
Deerfield Management Company 1.22M $29.77M March 31, 2013
MORGAN STANLEY 1.21M $97.38M Sept. 30, 2015
BAILLIE GIFFORD & CO 1.19M $93.01M Sept. 30, 2014
CITADEL ADVISORS 1.19M $36.84M June 30, 2013
BlackRock Advisors 1.17M $36.27M June 30, 2013